ALiEM - Pharm Pearls

OCTOBER 30, 2024

Bupe Allergy Buprenorphine induction has been the mainstay of emergency department treatment of opioid use disorder for more than a decade [11, 12]. That discussion can be deferred until the patient is stable, the risk of such an event is mitigated, and other medications can be given for their withdrawal symptoms and pain.

HIV Treatment and Prevention Agents 161

HIV Treatment and Prevention Agents Inpatient Hospitals Diabetes 161

Pharmacy Times

JUNE 23, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Diabetes 32

Diabetes HIV Treatment and Prevention Agents Pharmacy Technician Compounding Pharmacies 32

Pharmacy Times

JUNE 16, 2025

Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents.

Inpatient 29

Inpatient HIV Treatment and Prevention Agents Pharmacy Technician Chemotherapy 29

Pharmacy Times

JUNE 10, 2025

3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. 2 REFERENCES 1.

Pharmacy Technician 29

Pharmacy Technician HIV Treatment and Prevention Agents Compounding Pharmacies Biosimilars 29

Pharmacy Times

JULY 3, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

HIV Treatment and Prevention Agents 32

HIV Treatment and Prevention Agents Pharmacy Technician Compounding Pharmacies Hospitals 32

Pharmacy Times

JULY 1, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

HIV Treatment and Prevention Agents 44

HIV Treatment and Prevention Agents Pharmacy Technician Insurance Coverage and Processing Specialty Pharmacies 44

Pharmacy Friday Pearls

MARCH 4, 2022

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Hospitals Packaging Immunity 40